Trader logo

Trxade Group Inc. (NASDAQ: MEDS) Uplists to Nasdaq, Expects Gross Proceeds of $5.2M from Common Stock Sale

Trxade announces pricing of a firm commitment public offering of 806,452 shares of its common stock

By InvestorBrandNetworkPublished 4 years ago 3 min read
1
  • Proceeds to be used as working capital and to fund future acquisitions
  • Company’s B2B online purchasing platform currently has 11,900 pharmacies registered and is registering 100+ New pharmacies per month

Trxade Group Inc. (NASDAQ: MEDS), an integrated drug delivery, procurement, and healthcare platform that offers healthcare buyers and sellers of pharmaceuticals increased profit margins, announced that its common stock has begun trading on the Nasdaq Capital Market under new ticker symbol ‘MEDS’, as of February 13, 2020. The company’s common stock will cease trading on the OTCQB.

The company also announced the pricing of a firm commitment public offering of 806,452 shares of its common stock at $6.50 per share. Trxade Group granted a 45-day option to underwriters to buy up to an additional 120,967 shares of common stock to cover overallotments, or post-reverse stock split. The offering was expected to close on or around February 18 (http://nnw.fm/nfIU9).

Before deducting offering expenses and underwriting reductions, Trxade Group expects gross proceeds of $5.2 million from the sale of common stock in the offering. The company intends to use the net proceeds from the offering for general purposes and working capital, as well as to possibly fund acquisitions of other products, companies or technologies.

Dawson James Securities, Inc., Dougherty & Company LLC, and View Trade Securities, Inc. are acting as the underwriters of the offering.

Trxade has developed a proprietary web-based e-commerce platform (S2P – Supplier to Pharmacy) that enables trade among pharmaceutical, accessory, and service buyers and sellers. The platform currently has about 11,500 pharmacies as registered users, through which it reaches between 12 million and 15 million patients. The company aims to reach most, if not all, of the estimated 24,000 independent pharmacies currently operating in the U.S., with combined pharmaceutical purchases of $93 billion per year. The U.S. pharmaceutical industry, which is worth $330 billion, is comprised of 1,500 state-licensed suppliers and more than 65,000 pharmacy facilities, 24,000 of which are independent.

The platform offers multiple benefits such as significant discounts that contribute to a 7-10 percent decrease in the annual purchase expenses for pharmacies; no registration and transaction fees for pharmacies; a simple and intuitive interface that helps pharmacies compare prices and select the best offer with guaranteed security for purchases and payments. Revenue is generated from two primary sources: the growing number of registered users and an increase in the platform’s utilization rate among registered users. The company is adding over 100 pharmacies to its platform per month and has plans to soon provide access to other healthcare providers, such as hospitals, veterinary clinics and long-term care facilities.

The U.S. healthcare market is currently valued around $4 trillion. As the general population ages, further growth is expected, which in turn will have increasing impact on consumers as out-of-pocket expenses rise as well. Trxade aims to lower prescription drug costs by attacking the inefficient value chain, delivering drugs directly to independent pharmacists and consumers, and offering efficient purchasing and price transparency. Its integrated drug procurement, delivery and healthcare platform also delivers increased profit margins.

Founded in 2010, the company is comprised of three synergistic operating platforms: the B2B trading platform with 11,900 registered pharmacies, licensed virtual Wholesale and Mail Order Pharmacy capabilities including the mobile app DelivMeds, as well as the newly acquired assets of Bonum Health, a telemedicine platform.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)

New York, New York

www.NetworkNewsWire.com

212.418.1217 Office

[email protected]

NetworkNewsWire is part of the InvestorBrandNetwork.

investing
1

About the Creator

InvestorBrandNetwork

The InvestorBrandNetwork (IBN) is comprised of 40+ investor focused brands and offers a comprehensive suite of corporate communications solutions that reach new audiences on an ongoing focus basis. Full disclaimers: http://bit.ly/2S7w1sC

Reader insights

Be the first to share your insights about this piece.

How does it work?

Add your insights

Comments

There are no comments for this story

Be the first to respond and start the conversation.

Sign in to comment

    Find us on social media

    Miscellaneous links

    • Explore
    • Contact
    • Privacy Policy
    • Terms of Use
    • Support

    © 2024 Creatd, Inc. All Rights Reserved.